In the IMPACT trial, pemvidutide achieved mean weight losses of 4.8% and 5.8% with 1.2 and 1.8 mg doses respectively at 24 weeks, compared to 0.5% with placebo, with weight loss curves showing no evidence of plateauing, suggesting continued benefit with longer treatment [49-51]
Other considerations include if this class of medications is dropped from coverage, patients on the drugs will need to find other ways to pay for it if they want to continue, the affordability and availability of the medications, and what will the long-term impact be if patients stop taking the medications suddenly
Even if studies do not query subjects for heartburn and reflux and most dont all GI GLP-1 side-effects lead to acid reflux, both esophageal reflux and respiratory reflux
Tricare covers Trulicity, Ozempic, Mounjaro and Victoza to treat type 2 diabetes, with prior authorization
You have a known allergy to liraglutide or any inactive ingredient in Saxenda
Medicare explicitly excludes coverage for weight-loss medications (unless there are associated cardiovascular risks)